Splice-region antisense composition and method
AssigneeSarepta Therapeutics, Inc.
InventorsPatrick L. Iversen, Robert Hudziak
Life of this patent
Estimating the term…
Abstract
Antisense compositions targeted against an mRNA sequence coding for a selected protein, at a region having its 5′ end from 1 to about 25 base pairs downstream of a normal splice acceptor junction in the preprocessed mRNA, are disclosed. The antisense compound is RNase-inactive, and is preferably a phosphorodiamidate-linked morpholino oligonucleotide. Such targeting is effective to inhibit natural mRNA splice processing, produce splice variant mRNAs, and inhibit normal expression of the protein.
Claims10
An antisense compound composed of a 2′-O-methyl modified backbone and a base sequence of 12 to 25 nucleotide bases which is complementary to a target region within one exon of multiple exons of a preprocessed mRNA encoding a human protein, wherein the 5′-end of the target region is 12 bases downstream of a normal splice acceptor site in said preprocessed mRNA.
Dependencies are inferred from the claim text.